OBJECTIVE: The goal of this study was to examine the association of the antiinflammatory interleukin-10 (IL-10) with risk of cardiovascular disease (CVD). METHODS AND RESULTS: In the PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) cohort, we related baseline concentrations of circulating IL-10 to risk of CVD events in a nested case (n=819)-control (n=1618) study of 3.2 years of follow-up. Circulating IL-10 showed few strong associations with classical risk factors but was positively correlated with IL-6 and C-reactive protein. IL-10 was positively associated with risk of CVD events (odds ratio [OR] 1.17, 95% CI 1.05 to 1.31 per unit increase in log IL-10) after adjusting for classical risk factors and C-reactive protein. Furthermore, IL-10 was associated more strongly with CVD risk among those with no previous history of CVD (OR 1.42, 95% CI 1.18 to 1.70), compared with those with previous CVD (OR 1.04, 95% CI 0.90 to 1.19; P=0.018). Overall, IL-10 showed a modest ability to add discrimination to classical risk factors (C-statistic +0.005, P=0.002). CONCLUSIONS: Baseline circulating levels of the antiinflammatory IL-10 are positively associated with risk of CVD among the elderly without prior CVD events, although the association is less evident in those with a history of CVD. Additional epidemiological and mechanistic studies investigating the role of IL-10 in CVD are warranted.
RCT Entities:
OBJECTIVE: The goal of this study was to examine the association of the antiinflammatory interleukin-10 (IL-10) with risk of cardiovascular disease (CVD). METHODS AND RESULTS: In the PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) cohort, we related baseline concentrations of circulating IL-10 to risk of CVD events in a nested case (n=819)-control (n=1618) study of 3.2 years of follow-up. Circulating IL-10 showed few strong associations with classical risk factors but was positively correlated with IL-6 and C-reactive protein. IL-10 was positively associated with risk of CVD events (odds ratio [OR] 1.17, 95% CI 1.05 to 1.31 per unit increase in log IL-10) after adjusting for classical risk factors and C-reactive protein. Furthermore, IL-10 was associated more strongly with CVD risk among those with no previous history of CVD (OR 1.42, 95% CI 1.18 to 1.70), compared with those with previous CVD (OR 1.04, 95% CI 0.90 to 1.19; P=0.018). Overall, IL-10 showed a modest ability to add discrimination to classical risk factors (C-statistic +0.005, P=0.002). CONCLUSIONS: Baseline circulating levels of the antiinflammatory IL-10 are positively associated with risk of CVD among the elderly without prior CVD events, although the association is less evident in those with a history of CVD. Additional epidemiological and mechanistic studies investigating the role of IL-10 in CVD are warranted.
Authors: James D Wilkinson; Paige L Williams; Wendy Yu; Steven D Colan; Armando Mendez; Justin P V Zachariah; Russell B Van Dyke; William T Shearer; Renee E Margossian; Steven E Lipshultz Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Brandie D Taylor; Roberta B Ness; Mark A Klebanoff; Gong Tang; James M Roberts; David M Hougaard; Kristin Skogstrand; Catherine L Haggerty Journal: Pregnancy Hypertens Date: 2018-02-24 Impact factor: 2.899
Authors: Andreas G Moraitis; Lita A Freeman; Robert D Shamburek; Robert Wesley; Wyndham Wilson; Cliona M Grant; Susan Price; Stephen Demosky; Seth G Thacker; Abdalrahman Zarzour; Ronald L Hornung; Frank Pucino; Gyorgy Csako; Cheryl Yarboro; Iain B McInnes; Takashi Kuroiwa; Dimitrios Boumpas; V Koneti Rao; Gabor G Illei; Alan T Remaley Journal: J Clin Lipidol Date: 2014-10-05 Impact factor: 4.766
Authors: Paul Welsh; David Preiss; Suzanne M Lloyd; Anton J de Craen; J Wouter Jukema; Rudi G Westendorp; Brendan M Buckley; Patricia M Kearney; Andrew Briggs; David J Stott; Ian Ford; Naveed Sattar Journal: Diabetologia Date: 2014-09-30 Impact factor: 10.122